Lyra Therapeutics, Inc. — Net Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a58e620f-ac27-4381-ac33-d93c38e3c285/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-28.9M | 2025-01-01 – 2025-12-31 | evidence 0001327273-26-000003 |
| FY 2024 | $-93.4M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-038751 |
| FY 2023 | $-62.7M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-035047 |
| FY 2022 | $-55.3M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-010632 |
| FY 2021 | $-43.5M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-009187 |
| FY 2020 | $-22.1M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-011767 |
| FY 2019 | $-16.3M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-011767 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Lyra Therapeutics, Inc. — all facts · Revenue · Operating Income